REGULATORY
FRI, NOV 12, 2021 09:00 CET
RLS GLOBAL AB (publ) INTERIM REPORT, Q3, 2021
JULY 1st – SEP 30th
- Net sales amounted to TSEK 132 (TSEK 793)
- Earnings before interest and taxes (EBIT) amounted to MSEK -6,2 (MSEK -5,6)
- Earning per share before dilution at SEK -0,09 (SEK-0,08)
- Cash flow from operating activities amounted to MSEK 8,6 (MSEK-4,2)
- Liquid assets at the end of the period MSEK 16,4 (MSEK 25,9)
- Equity ratio was 86% (90%)
JAN 1st _ SEP 30th
- Net sales amounted to TSEK 472 (TSEK 1 905)
- Earnings before interest and taxes (EBIT) amounted to MSEK -4,0 (MSEK -15,0)
- Earning per share before dilution at SEK -0,06 (SEK-0,23)
- Cash flow from operating activities amounted to MSEK -3,4 (MSEK-15,2)
- Liquid assets at the end of the period MSEK 16,4 (MSEK 25,9)
- Equity ratio was 86% (90%)
SUMMARY OF EVENTS DURING THIRD QUARTER
- Activities in order to receive reimbursement in the European countries are in progress.
- The integration process with ConvaTec is in progress according to plan.
- RLS has reactivated R&D activities with special focus on burns and pressure ulcers.
- To meet future demand, RLS has initiated a project with the aim to automatize the production and improve the COGS.
COVID-19
- RLS experiences an opening within the health care sector. However, there are still restrictions due to the effect of the pandemic.
TRADING PLACE AND CERTIFIED ADVISER
RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. During the period 2012–2017, the company was listed on Aktietorget.
CONTACT INFORMATION
Karin Fischer, CEO
E-mail: karin.fischer@rlsglobal.se
Telephone: +46 702 48 46 51
Eva Jagenheim, CFO
E-mail: eva.jagenheim@rlsglobal.se
Telephone: +46 730 23 13 57
PUBLICATION
This information was submitted for publication through the agency of the above contact person, at 09.00 CET on Nov 12th, 2021.
